

Ref: FOI/GS/ID 8896

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

28 February 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to renal cell carcinoma and melanoma.

You asked:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- a. Avelumab + Axitinib*
- b. Axinitib*
- c. Cabozantinib*
- d. Everolimus*
- e. Lenvatinib + Everolimus*
- f. Nivolumab monotherapy*
- g. Nivolumab + Cabozantinib*
- h. Nivolumab + Ipilimumab*
- i. Pazopanib*
- j. Pembrolizumab monotherapy*
- k. Pembrolizumab + Lenvatinib*
- l. Pembrolizumab + Axitinib*
- m. Radiotherapy only*
- n. Sunitinib*
- o. Temsirolimus*
- p. Tivozanib*
- q. Other active systemic anti-cancer therapy*
- r. Palliative care only*

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- a. Cobimetinib*
- b. Dabrafenib*
- c. Dabrafenib + Trametinib*

- d. *Dacarbazine*
- e. *Denosumab*
- f. *Encorafenib + Binimetinib*
- g. *Ipilimumab monotherapy*
- h. *Ipilimumab + Nivolumab*
- i. *Nivolumab monotherapy*
- j. *Nivolumab + Relatlimab*
- k. *Pembrolizumab*
- l. *Trametinib*
- m. *Vemurafenib*
- n. *Vemurafenib + Cobimetinib*
- o. *Other active systemic anti-cancer therapy*
- p. *Palliative care only*

Q3. *Does you trust participate in any clinical trials for the treatment of melanoma? If so please provide the name of each trial and number of patients that are taking part?*

Trust response:

Q1	
a.	2
b.	7
c.	4
d.	6
e.	0
f.	6
g.	0
h.	4
i.	8
j.	3
k.	10
l.	0
m.	15
n.	1
o.	0
p.	0
q.	0
r.	5
Q2	
a.	0
b.	1
c.	24
d.	1
e.	0
f.	13
g.	0
h.	9

i.	9
j.	0
k.	52
l.	0
m.	1
n.	0
o.	3
p.	0

3. DANTE (Duration of Anti-PD1 therapy for melanoma) (IRAS 230556)
Closed to recruitment – in follow up, 5 participants recruited.